21 – 30 of 32
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2016
-
Mark
Current view and outcome of ITI therapy : A change over time?
(
- Contribution to journal › Article
-
Mark
Does the intensity and quality of treatment and not only the factor VIII level influence global hemostasis in patients with hemophilia A?
(
- Contribution to journal › Letter
- 1999
-
Mark
The prothrombin gene G20210A mutation and the platelet glycoprotein IIIa polymorphism PlA2 in patients with central retinal vein occlusion
(
- Contribution to journal › Article
- 1997
-
Mark
Activated protein C resistance caused by a common factor V mutation has a single origin
(
- Contribution to journal › Article
- 1996
-
Mark
Pharmacokinetics and delayed experimental anti-thrombotic effect of two domain non-glycosylated tissue factor pathway inhibitor
(
- Contribution to journal › Article
-
Mark
High prevalence of the FVR506Q mutation causing APC resistance in a region of southern Sweden with a high incidence of venous thrombosis.
(
- Contribution to journal › Letter
- 1995
-
Mark
Treatment with recombinant human erythropoietin induces a moderate rise in hematocrit and thrombin antithrombin in healthy subjects
(
- Contribution to journal › Article
-
Mark
Effects of hemodialysis and longterm erythropoietin treatment on protein C, and on free and total protein S
(
- Contribution to journal › Article
- 1993
-
Mark
Tissue factor pathway inhibitor (TFPI) and its response to heparin in patients with spontaneous deep vein thrombosis
(
- Contribution to journal › Article
- 1983
-
Mark
The effects of plasmin and protein Ca on factor VIII:C and VIII:CAg
(
- Contribution to journal › Article